While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

根据AI大模型测算康辰药业后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股有吸筹现象，但吸筹力度不强。舆情分析来看，目前市场情绪悲观。

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Bavarian Nordic's own pipeline is led by its universal COVID-19 booster candidate, which is due to start phase 3 later this year, and respiratory syncytial virus (RSV) candidate that should ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...

11月8日，康辰药业涨0.28%，成交额4808.87万元，换手率1.23%，总市值39.79亿元。 根据AI大模型测算康辰药业后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股获筹码青睐，且集中度渐增。舆情分析来看，目前市场情绪悲观。 1、公司参股的优锐医药是Bavarian Nordic公司中国区及亚洲部分地区的唯一合作 ...

Jynneos是一种用于预防天花（smallpox）和猴痘（mpox）的疫苗，由丹麦公司Bavarian Nordic开发。它是目前唯一获得广泛批准并上市的mpox疫苗，尤其是在2022年mpox疫情期间引起了广泛关注。

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...